24 articles found
New Mexico becomes testing ground for SAMHSA-vetted digital recovery platform with dedicated teen version, offering 24/7 peer support and crisis intervention through smartphones.
New Child Trends analysis shows youth overdose deaths dropped 37% since 2023, with rates now lower than before the pandemic despite fentanyl's continued spread.
UC San Diego and SDSU study of 2.8 million students finds local flavor bans reduce e-cigarette use by 20% with no increase in cigarette smoking, challenging industry arguments.
Wake Forest research reveals e-cigarette taxes reduced vaping among heterosexual teens by 3-4 percentage points, yet had no effect on LGBQ youth who use nicotine to cope with bullying and emotional distress.
New ASAM Criteria volume establishes dedicated clinical standards for youth SUD treatment, emphasizing brain development, family engagement, and integrated mental health care
DEA reports 1,400 carfentanil identifications in 2025, up from just 54 in 2022. The veterinary tranquilizer, 100 times stronger than fentanyl, is killing unsuspecting users as China cracks down on fentanyl precursors.
More than 200 residents protest proposed 122-bed addiction treatment facility funded by California's Proposition 1, highlighting tensions between statewide mental health expansion and neighborhood concerns
North Carolina awards federal block grants to 12 community organizations for rural treatment, crisis response, and justice-involved recovery programs targeting 1.4 million residents with substance use disorders.
Ann Arbor-based online addiction provider now treats kratom and 7-hydroxymitragynine dependence through app-based platform, addressing regulatory gap as FDA restricts potent derivatives but leaf products remain unregulated nationwide.
American Society of Addiction Medicine releases first comprehensive update to youth substance use disorder treatment standards in over a decade, addressing telehealth, trauma-informed care, and medication access.
Swedish registry analysis of 100,000 individuals finds GLP-1 medications reduce depression by 44%, anxiety by 38%, and substance use disorders by 47%.
AB 602 requires California public universities to provide addiction treatment rather than punishment when students seek help for overdoses, effective July 2026.
Psychostimulants, primarily methamphetamine, overtook opioids as Iowa's leading overdose cause in 2024. Without a Narcan equivalent, public health officials confront new treatment challenges.
Bipartisan DETECT Nitazenes Act introduced in Congress would enhance detection technology for emerging class of synthetic opioids linked to over 1,000 deaths in UK.
New study finds NET Device reduces opioid and stimulant use for 3 months post-treatment, offering hope for polysubstance addiction amid no approved medications for stimulants
Eight new mental health and drug treatment facilities will receive Proposition 1 funding, including sobering centers and residential programs across the Bay Area
VA study of 600,000 patients finds GLP-1 medications like Ozempic reduce substance use disorder risk by 15-20%, suggesting a common biological pathway underlying all addictions.
New national survey reveals 18 states mandate recovery assessments in treatment facilities, but federal reporting burdens and staffing shortages slow broader adoption.
Washington University analysis of 600,000+ VA patients finds GLP-1s tied to 50% reduction in drug-related deaths and lower risk across alcohol, opioid, cocaine, and nicotine use disorders.
Washington University research shows uMAT-R app reduced opioid and drug use by 50% in people experiencing housing insecurity, addressing critical gap in treatment access.
In a landmark policy shift, the FDA announced it will approve new drugs based on a single rigorous trial plus confirmatory evidence—a change that could accelerate development of therapies for opioid use disorder, alcohol addiction, and stimulant dependence.
As cocaine and methamphetamine become contaminated with fentanyl, researchers argue that contingency management and culturally adapted harm reduction are essential—yet remain vastly underutilized across the United States.
Digital therapeutics for substance use disorders are gaining traction as researchers identify key strategies to improve engagement and outcomes, with apps reaching patients beyond traditional clinic walls.
New Jersey lawmakers unanimously approve trio of bills to regulate addiction treatment industry, addressing concerns raised in 2024 state investigation into facility operations and peer recovery programs.